SCHEMBL1367501

SCHEMBL1367501

Cc1nc(Nc2n[nH]c3c2CN(C(=O)N[C@@H]2C[C@H]2c2ccccc2)C3(C)C)c2sccc2n1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PAK4 O96013 20/20 1.00
OPRM1 P35372 1/20 1.00
PLK4 O00444 1/20 0.65
CHEK1 O14757 1/20 0.65
AURKA O14965 1/20 0.65
GAK O14976 1/20 0.65
RPS6KA5 O75582 1/20 0.65
RPS6KA4 O75676 1/20 0.65
STK16 O75716 1/20 0.65
PAK3 O75914 1/20 0.65
CDKL5 O76039 1/20 0.65
PRKD3 O94806 1/20 0.65
LATS1 O95835 1/20 0.65
CHEK2 O96017 1/20 0.65
NTRK1 P04629 1/20 0.65
TP53 P04637 1/20 0.65
PRKCG P05129 1/20 0.65
PRKCB P05771 1/20 0.65
FYN P06241 1/20 0.65
YES1 P07947 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13454839 1.00 PAK4 (1.00) PAK4OPRM1PLK4CHEK1AURKA
SCHEMBL1941293 1.00 PAK4 (1.00) PAK4OPRM1PLK4CHEK1AURKA
SCHEMBL15247481 0.92 PAK4 (1.00) PAK4OPRM1
SCHEMBL12143681 0.92 PAK4 (1.00) PAK4OPRM1
SCHEMBL1367036 0.92 PAK4 (1.00) PAK4OPRM1
SCHEMBL1367038 0.92 PAK4 (1.00) PAK4OPRM1
SCHEMBL1943116 0.90 PAK4 (1.00) PAK4OPRM1
SCHEMBL1943115 0.90 PAK4 (1.00) PAK4OPRM1
SCHEMBL12145124 0.90 PAK4 (0.81) PAK4OPRM1
SCHEMBL12143679 0.89 PAK4 (1.00) PAK4OPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8530652-B2 Pyrrolopyrazoles, potent kinase inhibitors AGOURON PHARMACEUTICALS, INC. (US) 2013-09-10 US disclosed
US-8530652-B2 Pyrrolopyrazoles, potent kinase inhibitors AGOURON PHARMACEUTICALS, INC. (US) 2013-09-10 US disclosed
US-20120264751-A1 PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS AGOURON PHARMACEUTICALS, INC. 2012-10-18 US disclosed
US-20120264751-A1 PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS AGOURON PHARMACEUTICALS, INC. 2012-10-18 US disclosed
US-8067591-B2 Pyrrolopyrazole, potent kinase inhibitors AGOURON PHARMACEUTICALS, INC. (US) 2011-11-29 US disclosed
US-8067591-B2 Pyrrolopyrazole, potent kinase inhibitors AGOURON PHARMACEUTICALS, INC. (US) 2011-11-29 US disclosed
US-8067591-B2 Pyrrolopyrazole, potent kinase inhibitors AGOURON PHARMACEUTICALS, INC. (US) 2011-11-29 US disclosed
EP-1838718-B1 PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS PFIZER (US) 2011-06-15 EP disclosed
US-20100222342-A1 PYRROLOPYRAZOLE, POTENT KINASE INHIBITORS ZHANG JUNHU 2010-09-02 US disclosed
US-20100222342-A1 PYRROLOPYRAZOLE, POTENT KINASE INHIBITORS ZHANG JUNHU 2010-09-02 US disclosed
US-20100222342-A1 PYRROLOPYRAZOLE, POTENT KINASE INHIBITORS ZHANG JUNHU 2010-09-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120264751-A1 PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS PAK4, PAK5, PAK3 PAK4 1/4885OPRM1 4322/4885PLK4 108/4885
US-20100222342-A1 PYRROLOPYRAZOLE, POTENT KINASE INHIBITORS PAK4, PAK5, PAK3 PAK4 1/4885OPRM1 4150/4885PLK4 97/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.